GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » EBITDA Margin %

Ectin Research AB (XSAT:ECTIN B) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ectin Research AB's EBITDA for the three months ended in Mar. 2024 was kr-2.29 Mil. Ectin Research AB's Revenue for the three months ended in Mar. 2024 was kr0.00 Mil. Therefore, Ectin Research AB's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.


Ectin Research AB EBITDA Margin % Historical Data

The historical data trend for Ectin Research AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ectin Research AB EBITDA Margin % Chart

Ectin Research AB Annual Data
Trend Aug19 Aug20 Dec22 Dec23
EBITDA Margin %
- - - -

Ectin Research AB Quarterly Data
Aug19 Aug20 Mar21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ectin Research AB's EBITDA Margin %

For the Biotechnology subindustry, Ectin Research AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ectin Research AB's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ectin Research AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Ectin Research AB's EBITDA Margin % falls into.



Ectin Research AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Ectin Research AB's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-17.198/0
= %

Ectin Research AB's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-2.288/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ectin Research AB  (XSAT:ECTIN B) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Ectin Research AB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Ectin Research AB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ectin Research AB (XSAT:ECTIN B) Business Description

Traded in Other Exchanges
N/A
Address
Pepparedsleden 1, Molndal, SWE, 431 83
Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB (XSAT:ECTIN B) Headlines

No Headlines